Anagenesis Announces Professor Helen Blau, joining the scientific team to develop novel Therapies for Muscle Diseases

BOSTON, USA and ILLKIRCH GRAFFENSTADEN, France – September 6, 2016 – Anagenesis announced today that "Professor Helen M. Blau is joining its scientific team as co-founder. Helen Blau is currently the Donald E. and Delia B. Baxter Foundation Professor and Director of the Baxter Laboratory for Stem Cell Biology at Stanford University School of Medicine. She brings expertise in the field of stem cells, muscle biology and regenerative medicine".

"We are proud to welcome Pr H Blau, a world renowned scientist in the field of muscle biology", said Olivier Pourquié, President of the SAB, co-founder of Anagenesis and co-inventor of the P2MC technology.

Blau was born in London, England and grew up in Europe. She received her B.A. from the University of York, England, her Ph.D. from Harvard University, and was a postdoctoral fellow at UCSF before joining the faculty at Stanford University. She is a fellow of the American Association for the Advancement of Science and a member of the American Academy of Arts and Sciences, the National Academy of Medicine, and the National Academy of Sciences. She served as President of the American Society for Developmental Biology and President of the International Society of Differentiation. She was a member of the Harvard Board of Overseers, the Ellison Medical Foundation Scientific Advisory Board, the Council of the Institute of Aging of the NIH, the Council of National Academy of Medicine, and currently serves on the Council of the American Academy of Arts and Sciences. Blau is a recipient of numerous awards, among them the FASEB Excellence in Science Award, McKnight Innovations Award, Stanford's Office of Technology Licensing Innovator Award, an Honorary Doctorate from the University of Nijmegen, and an American Association for Cancer Research Irving Weinstein Foundation Distinguished Lectureship.

"I am excited to work with Olivier, Jean-Yves and the excellent scientists at Anagenesis to enhance muscle regeneration," said Helen Blau, Baxter Foundation Professor for Stem Cell Biology at Stanford University. "Their pioneering stem cell technology is based on fundamental developmental principles and is state-of-the-art. I have worked for decades with families suffering from Duchenne Muscular Dystrophy (DMD), a devastating disease, and carried out a phase I clinical trial for Duchenne Muscular Dystrophy. The potential for using Anagenesis induced pluripotent stem cells as a cell therapy for muscular dystrophies

such as Duchenne Muscular Dystrophy is immense. Their myogenic cell platform also holds tremendous promise for drug screening for the treatment of muscle wasting due to aging (sarcopenia) and cancer (cachexia). I am extremely pleased to have the opportunity to contribute to Anagenesis' work, which is poised to profoundly impact therapeutic strategies of the most debilitating muscle degenerative disorders".

"We are excited to welcome Pr Helen Blau said Jean-Yves Bonnefoy, PhD, President and Chief Executive Officer of Anagenesis. Her knowledge and experience in the field of stem cells and muscle biology will be an asset for Anagenesis development in the coming years."

About Anagenesis Biotechnologies

Anagenesis Biotechnologies is a private company developing new treatments against muscle diseases (genetic such as DMD and chronic such as sarcopenia and cachexia). The company was cofounded by Dr. Olivier Pourquié, a worldwide key opinion leader in the field of musculoskeletal development and stem cells. Olivier Pourquié is a Professor at Harvard Medical School and the Brigham and Women's Hospital and a member of the Harvard Stem Cell Institute. Anagenesis Biotechnologies is backed by a solid, experienced team led by its President & CEO, Dr. Jean-Yves Bonnefoy, coming from the Pharma & Biotech industry. Anagenesis Biotechnologies in Illkirch, France, is now focusing on HTS and HCS screens, while its newly formed US-subsidiary in Boston, MA, Anagenesis Biotherapies Inc., is developing the cell therapy approaches. For more information, please visit www.anagenesis-biotech.com.

Anagenesis has secured two strategic partnerships this year. One with Ksilink on highthroughput screening for novel small molecules for DMD and one with CRISPR Therapeutics to develop cell-based therapies for muscle diseases including DMD.

Anagenesis' proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology allows for the efficient, reproducible and chemically defined differentiation of pluripotent cells into skeletal muscle, brown fat, dermis, endothelial cells, cartilage and bone. The P2MC technology was developed with the support of AFM-telethon, INSERM-Transfert, CNRS and Université de Strasbourg.

MEDIA CONTACT:

Jean-Yves Bonnefoy
President & CEO
+33 620 885 092
jybonnefoy@anagenesis-biotech.com